Conducted between June 2011 and March 2013 at 191 sites in 27 countries in Europe, North America, South America, Asia, and Australia this was a randomised, placebo-controlled trial designed to evaluate the efficacy and safety of 3mg liraglutide 'injected subcutaneously once daily, as an adjunct to a reduced-calorie diet and increased physical activity, for weight management in overweight or obese adults who did not have diabetes at baseline.' A total of 3,731 individuals participated in the trial, of whom 2,487 were assigned to lifestyle intervention plus liraglutide and 1,244 to lifestyle intervention with a placebo
Some people cannot absorb enough vitamin B12
We recommend planning your experiments within this timeframe to ensure you're always working with a maximally effective compound
Be realistic: Benefits in humans are not proven and research is ongoing
A quarterly update to the HCPCS Level II code set adds 32 new drug and biological codes this October